newsLarge scale registry shows atrial fibrillation management is suboptimal and unequal around the worldNew one-year follow-up results from the global RE-LY AF registry...29 August 2012 | By Boehringer IngelheimNew one-year follow-up results from the global RE-LY AF registry...
newsAF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarinPradaxa® is associated with a substantially shorter interruption of oral…18 June 2012 | By Boehringer IngelheimPradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...